Diagnostic evaluation of the adrenal incidentaloma: Decision and cost- effectiveness analyses

Journal of Nuclear Medicine

Volumn 39, Issue 4, 1998, Pages 707-712

  Dwamena, Ben A ^b   Kloos, Richard T ^b   Fendrick, A Mark ^b   Gross, Milton D ^a   Francis, Isaac R ^b   Korobkin, Melvyn T ^b   Shapiro, Brahm ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

Adrenal mass; Adrenocortical scintigraphy; Cost effectiveness analysis; Incidentaloma

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131;

ADRENAL TUMOR; ARTICLE; CANCER RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADOSTEROL; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL ADENOMA; BIOPSY, NEEDLE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031901580     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Copeland PM. The incidentally discovered adrenal mass. Ann Intern Med 1983;98: 940-945.
2. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocrinal Rev 1995;16:460-484.
3. King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 1979;44:239-244.
4. Nosher JL, Amorosa JK, Leiman S, Plafker J. Fine-needle aspiration of the kidney and adrenal gland. J Urol 1982;128:895-899.
5. Tang C, Gray G. Adrenocortical neoplasms. Prognosis and morphology. Urology 1975;5:691-695.
6. Dominguez-Gadea L, Diez L, Bas C, Crespo A. Differential diagnosis of solid adrenal masses using adrenocortical scintigraphy. Clin Radiol 1994;49:796-799.
7. Gaboardi F, Carbone M, Bozzola A, Galli L. Adrenal incidentalomas: what is the role of fine-needle biopsy? Int Urol Nephral 1991;23:197-207.
8. Gross MD, Shapiro B, Francis IR, et al. Scintigraphic evaluation of clinically silent adrenal masses. J Nucl Med 1994;35:1145-1152.
9. Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 1995;19:434-439.
10. Zornoza J, Ordonez N, Bernardino MH, Cohen MA. Percutaneous biopsy of adrenal tumors. Urology 1981;18:412-416.
11. Heaston DK, Handel DB, Ashton PR, Korobkin M. Narrow gauge needle aspiration of solid adrenal masses. Am J Roentgenol 1982;138:1143-1148.
12. Katz RL, Patel S, Mackay B, Zornoza J. Fine-needle aspiration cytology of the adrenal gland. Acta Cytol 1984;28:269-282.
13. Bernardino ME, Walther MM, Phillips VM, et al. CT-guided adrenal biopsy: accuracy, safety, and indications. Am J Roentgenol 1985;144:67-69.
14. Yankaskas BC, Staab EV, Craven MB, Blatt PM, Sokhandan M, Carney CM. Delayed complications from fine-needle biopsies of solid masses of the abdomen. Invest Radiol 1986;21:325-328.
15. Kane NM, Korobkin M, Francis IR, Quint LE, Cascade PN. Percutaneous biopsy of left adrenal masses: prevalence of pancreatitis after anterior approach. Am J Roentgenol 1991;157:777-780.
16. Welch TJ, Sheedy Pn, Stephens DH, Johnson CM, Swensen SJ, Sheedy PN. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994;193: 341-344.
17. Silverman SG, Mueller PR, Pinkney LP, Koenker RM, Seltzer SE. Predictive value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology 1993;187: 715-718.
18. Hagen MD. Decision analysis: a review. Fam Med 1992;24:349-54.
19. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316:250-258.
20. Phelps CE, Mushlin AI. Focusing technology assessment using medical decision theory. Med Decision Making 1988;8:279-289.
21. Powe NR. Economic and cost-effectiveness investigations of radiologic practices. Radiology 1994;192:11-18.
22. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
23. Ament A, Hasman A. Optimal test strategy in the case of two tests and one disease. Int J Biomed Comput 1993;33:179-197.
24. Hershey JC, Cebul RD, Williams SV. Clinical guidelines for using two dichotomous tests. Med Decision Making 1986;6:68-78.
25. Lee M, Hahn P, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size and observer analysis. Radiology 1991; 179:415-418.
26. Singer AA, Obuchowski NA, Einstein DM, Paushter DM. Metastasis or adenoma? Computed tomographic evaluation of the adrenal mass. Cleveland Clin J Med 1994;61:200-205.
27. van Erkel AR, van Gils AP, Lequin M, Kruitwagen C, Bloem JL, Falke TH. CT and MR distinction of adenomas and nonadenomas of the adrenal gland. J Comput Assist Tomogr 1994;18:432-438.
28. Korobkin M, Brodeur F, Yutzy G, et al. Differentiation of Adrenal Adenomas from Nonadenomas using CT Attenuation values. Am J Roentgenol 1996;166:531-536.
29. Mitchell DG, Crovello M, Matteucci T, Petersen RO, Miettinen MM. Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology 1992; 185:345-351.
30. Bilbey JH, McLoughlin RF, Kurkjian PS, et al. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. Am J Roentgenol 1995;164:637-642.
31. Mayo-Smith WW, Lee MJ, McNicholas MM, Hahn PF, Boland GW, Saini S. Characterization of adrenal masses (<5 cm) by use of chemical shift MR imaging: observer performance versus quantitative measures. Am J Roenlgenol 1995;165: 91-95.
32. Outwater EK, Mitchell DG. Differentiation of adrenal masses with chemical shift MR imaging [Letter]. Radiology 1994;193:877-878.
33. Francis I, Smid A, Gross M, Shapiro B, Naylor B, Glazer G. Adrenal masses in oncologic patients: functional and morphologic evaluation. Radiology 1988;166:353-356.
34. Gross MD, Wilton GP, Shapiro B, et al. Functional and scintigraphic evaluation of the silent adrenal mass. J Nucl Med 1987;28:1401-1407.
35. Gross MD, Shapiro B, Bouffard JA, et al. Distinguishing benign from malignant euadrenal masses. Ann Intern Med 1988;109:613-618.
36. Dominguez-Gadea L, Diez L, Crespo A. Differential diagnosis of solid adrenal masses using adrenocortical scintigraphy. Clin Radiol 1994;49:796-799.
37. Nakajo M, Nakacelppin Y, Yonejura R, Icuashita S, Goto T. The role of adrenocortical scintigraphy in the evaluation of unilateral incidentally discovered adrenal and juxtaadrenal masses. Ann Nucl Med 1992;7:157-166.
38. Bardet S, Rohmer V, Margat A, et al. and the West France Study Group of Incidentalomas (WFSGI). Iodine-131-6 β-iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Clin Endocrinol 1996;44:587-596.
39. 75Se-6-selenomethyl/cho!esterol. Eur J Nucl Med 1991;18:817-823.
40. 131I-6β-iodomethylnoncholesterol [NP-59] scintigraphy. World J Surg 1997;21:36-40.
41. Patton DD, Woolfenden JM. A utility-based model for comparing the cost-effectiveness of diagnostic tests. Invest Radiology 1989;24:263-271.
42. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;13:147-154.